CTI BioPharma competitors

CTI BioPharma's competitors include Escient Pharmaceuticals, Omeros Corporation, Global Blood Therapeutics and Acticor Biotech
Add company...
CTI BioPharma
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers.
Escient Pharmaceuticals
Escient Pharmaceuticals is a biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications.
Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.
Global Blood Therapeutics
Global Blood Therapeutics (GBT) is dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders.
Acticor Biotech
Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke.
Founding Date
Founding Date
1992
Founding Date
N/A
Founding Date
1994
Founding Date
2012
Founding Date
2013
Type
Type
Public
Type
Private
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
Seattle, US HQ
Locations
San Diego, US HQ
Locations
Seattle, US HQ
Locations
South San Francisco, US HQ
Locations
Paris, FR HQ
Employees
Employees
100
Employees
N/A
Employees
154
Employees
9573% increase
Employees
913% increase
Valuation ($)
Valuation ($)
294.5 m
Valuation ($)
N/A
Valuation ($)
901.6 m
Valuation ($)
2.2 b
Valuation ($)
N/A
Twitter followers
Twitter followers
177
Twitter followers
N/A
Twitter followers
80
Twitter followers
N/A
Twitter followers
241

Financial

Revenue (est.)
Revenue (est.)
$25.1m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$64.8m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Net income
Net income
($45m) (FY, 2017)
Net income
N/A
Net income
($53.5m) (FY, 2017)
Net income
($117m) (FY, 2017)
Net income
N/A

Funding

Latest funding round
Latest funding round
N/A
Latest funding round
$ 40m (about 2 months ago)
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 2.1m (6 months ago)
Total funding raised
Total funding raised
$ 85.1m
Total funding raised
$ 40m
Total funding raised
$ 354.8m
Total funding raised
$ 88.7m
Total funding raised
$ 7.9m
For sources of this data, please see the company profileDownload Excel

View company profiles

Escient Pharmaceuticals
HQ
San Diego, US

Escient Pharmaceuticals is a biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications.

View company
Omeros Corporation
HQ
Seattle, US
Employees
154

Omeros Corporation is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.

View company
Global Blood Therapeutics
HQ
South San Francisco, US
Employees
95

Global Blood Therapeutics (GBT) is dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders.

View company
Acticor Biotech
HQ
Paris, FR
Employees
9↑ 13% increase

Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke.

View company